News & Updates

In the treatment of patients with mild-to-moderate COVID-19, adding fluvoxamine to favipiravir does not appear to prevent disease progression or improve certain outcomes, according to the results of an open-label study.

More evidence suggests that people exposed to more air pollution during the pandemic are at greater risk for COVID-19 infection, hospitalization, and death, but the exact mechanism behind the link is unknown.